• Genmab’s investigational Rina-S improved progression-free survival versus chemotherapy in the Phase 3 RAINFOL-02 trial in platinum-resistant ovarian cancer.
• Overall survival also improved significantly; benefits were clinically meaningful across both trial analysis populations.
• No new safety signals or unexpected safety concerns emerged.
• Results will be submitted for presentation at a future medical meeting, with regulatory discussions planned worldwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610231155PRIMZONEFULLFEED1001279615) on October 23, 2026, and is solely responsible for the information contained therein.